Currently, The Schall Law Firm is Actively Probing Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)Accesswire • 06/09/24
Presently, The Schall Law Firm is Conducting Investigations into Potential Securities Law Violations for the Advantage of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)Accesswire • 06/08/24
Currently, The Schall Law Firm is Undertaking Probes into Possible Securities Law Breaches for the Benefit of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC)Accesswire • 06/07/24
At Present, The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)Accesswire • 06/06/24
Currently, The Schall Law Firm Is Probing Allegations For Possible Securities Laws Breaches On Behalf Of Investors Of Blueprint Medicines Corporation (NASDAQ:BPMC)Accesswire • 06/05/24
The Schall Law Firm is Currently Investigating Claims on Behalf of Investors of Blueprint Medicines Corporation (NASDAQ:BPMC) for Potential Violations of Securities LawsAccesswire • 06/04/24
BPMC ONGOING INVESTIGATION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmAccesswire • 06/03/24
IMPORTANT ACTION UPDATE: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmAccesswire • 06/02/24
IMPORTANT ACTION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmAccesswire • 06/01/24
IMPORTANT ACTION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmAccesswire • 05/31/24
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)PRNewsWire • 05/30/24
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the FirmAccesswire • 05/30/24
Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual MeetingPRNewsWire • 05/23/24
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRNewsWire • 05/06/24
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/02/24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidancePRNewsWire • 05/02/24
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/25/24
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024PRNewsWire • 04/18/24
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted TherapeuticsPRNewsWire • 04/11/24
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual MeetingPRNewsWire • 02/23/24
Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 EarningsZacks Investment Research • 02/16/24